Quick Facts

• Primary Use: Management of allergic and non-allergic nasal symptoms.
• Relieves Symptoms Associated With: Seasonal and year-round rhinitis (e.g., hay fever).
• Target Symptoms: Nasal congestion, runny nose, sneezing, and nasal itchiness.
• Additional Relief: May assist in alleviating associated itchy and watery eyes.

Фликсоназе (Fluticasone Propionate nasal spray) is indicated for the management of nasal symptoms linked to both seasonal and perennial (year-round) allergic rhinitis. It is also used to address non-allergic rhinitis, providing a potential reduction in the associated discomfort.

The medication may assist in relieving key nasal symptoms, including congestion, sneezing, a runny nose, and itching. For patients experiencing seasonal allergies (hay fever), this spray contributes to the relief of these symptoms. By addressing the process associated with inflammation in the nasal passages, the product helps achieve an improvement in breathing and overall nasal comfort. It is important to note that this therapy controls the symptoms but does not offer a cure for these conditions.

Who can and cannot use Фликсоназе?

The eligibility for fluticasone propionate nasal spray is governed by strict regulatory classifications defining its authorized and prohibited populations, based on official government labeling.

Eligibility Scope

The medicine is generally allowed for adults, adolescents, and children aged 4 years and older. Use is not recommended in children under 4 years of age because safety and efficacy have not been established for this group according to regulatory authorities.

Contraindications and Restrictions

The absolute exclusion for use is a known hypersensitivity to fluticasone propionate or any other component in the formulation.

Eligibility is conditional in several populations:

• Nasal Integrity: Use is not recommended until healing is complete for patients with recent nasal septal ulcers, surgery, or trauma.
• Infection Status: Caution is advised for individuals with untreated local infections of the nasal mucosa (e.g., fungal, bacterial, viral).
• Physiological State: Use during pregnancy and lactation is conditional, requiring the potential benefit to outweigh the potential risk. Caution is also advised for patients with severe hepatic impairment due to the potential for increased systemic drug exposure.

Flixonase Interactions with other medicines and products

The officially documented interaction profile for Fluticasone Propionate nasal spray centers on its metabolic pathway, classified as a pharmacokinetic interaction. The medicine is a substrate of the Cytochrome P450 3A4 (CYP3A4) enzyme, which dictates the primary interaction constraints found in regulatory labeling.

Administration Restrictions

Co-administration with strong CYP3A4 inhibitors is formally not recommended by regulatory authorities. This restriction applies to medicines such as ritonavir and ketoconazole, which can drastically increase the systemic exposure (AUC and Cmax) of fluticasone propionate. The resulting increase in exposure can lead to systemic corticosteroid effects, including adrenal suppression.

Other Documented Interactions

Interaction Type	Interacting Substance/Condition	Official Regulatory Note
Pharmacodynamic	Other Corticosteroid Products	Risk of additive systemic corticosteroid effects from multiple sources.
Drug–Food	Grapefruit Juice	Inhibits CYP3A4, requiring restriction to avoid increased systemic exposure.
Population-Specific	Severe Liver Disease	Drug clearance may be slower, leading to increased systemic exposure.

No timing-based separation requirements (e.g., must be separated by X hours) are documented; the constraint is the avoidance of co-administration with strong inhibitors.

Genetic Regulation via the Glucocorticoid Receptor

The drug initiates its mechanism by acting as a high-affinity agonist at the Glucocorticoid Receptor (GR) found within the cells of the nasal lining. This activated drug-receptor complex translocates to the cell nucleus, where it executes transrepression, a key process that effectively inhibits the activity of pro-inflammatory transcription factors like Nuclear Factor-κB (NF-κB). This action fundamentally alters the cell’s protein synthesis instructions, reducing the transcription and synthesis of numerous pro-inflammatory proteins.

---

Suppression of the Inflammatory Cascade and Edema Control

The reduction in pro-inflammatory gene transcription modulates the complex local inflammatory cascade via multi-pathway inhibition. This mechanism results in the reduced accumulation and inhibition of the function of inflammatory cells, such as eosinophils and mast cells, and significantly reduces the synthesis and release of key chemical mediators like histamine, cytokines, and prostaglandins. By lowering the concentration of these mediators, the drug modifies the local blood vessel response, decreasing vascular permeability and reducing mucosal edema via decreased fluid extravasation. Because this mechanism depends on the slower process of gene expression change, the physiological magnitude increases gradually, reaching its maximum degree as the gene transcription-dependent mechanism fully manifests over several days.

Fluticasone Propionate, commonly associated with the brand name Flixonase, is administered by the intranasal route only, using an aqueous suspension nasal spray where each actuation delivers 50 mcg of the active ingredient. Proper usage relies upon a regular, scheduled pattern rather than intermittent use, as maximum therapeutic relief may not be achieved until after several days of treatment. The dosing regimen is defined by age group and the clinical need for control.

For adults and adolescents aged 12 years and older, the typical starting dose is 200 mcg per day, which is achieved by administering two sprays into each nostril once daily. Once adequate control is established, the instruction is to titrate the dose down to the lowest effective level that maintains symptom management, often resulting in a maintenance dose of 100 mcg per day. The maximum total daily dose for this population is 200 mcg.

Usage for pediatric patients aged 4 to 11 years begins at a level of 100 mcg per day (one spray per nostril once daily), and the use of the product is generally not recommended for children under 4 years. Procedural steps are specified to ensure consistent delivery: the device must be shaken gently before each use, and it must be primed before initial application or if it has not been used for seven days or more. A missed dose should be skipped entirely, and the regular schedule resumed without doubling the next dose. Furthermore, the spray unit must be discarded after delivering its specified number of metered sprays (e.g., 120 sprays) to maintain consistent dose delivery.

Research evidence / Overview of Studies for Flixonase (Fluticasone Propionate)

Evidence for Use in Seasonal and Perennial Allergic Rhinitis

Research on Flixonase has explored its use in people experiencing allergic rhinitis, including both seasonal allergies (like hay fever) and year-round (perennial) allergies. The evidence is primarily based on Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time when compared to a placebo. Researchers monitored changes in patient-reported outcomes describing perceived discomfort related to the nose, such as congestion, sneezing, itching, and a runny nose. Long-term studies, primarily focused on perennial rhinitis, have explored symptom patterns over periods extending up to a year.

The findings describe patterns observed in the studies related to the changes of these episodic and fluctuating symptoms over defined time intervals. This evidence contributes to the broader evidence landscape, describing how symptoms evolved in the observed populations during the study period. It is important to note that results apply only to the populations studied. Research on long-term outcomes beyond one year of continuous use remains limited.

Evidence for Use in Non-Allergic Rhinitis

Research has also explored non-allergic rhinitis—conditions where symptoms are present but an allergy cause has been ruled out. Research examined this condition, which is characterized by fluctuating manifestations, typically using dedicated RCTs over periods such as four weeks. The studies measured outcomes related to physical discomfort, particularly focusing on nasal congestion and chronic runny nose.

Research describes changes measured during the study period for these specific nasal outcomes. Findings indicate that the use of fluticasone propionate nasal spray was observed in some studies to be associated with these outcomes, including in perennial non-allergic rhinitis. The overall research base for non-allergic rhinitis is limited. Evidence quality varies across studies, and data for certain groups, such as those with vasomotor rhinitis, remain insufficient.

Evidence in Special Populations and Research Gaps

Flixonase was evaluated in studies involving children (aged four years and older) and adolescents, which provided insight into short-term changes in these younger groups. However, evidence is limited and certainty remains low for outcomes in the very youngest pediatric populations (below four years of age). Key limitations include the fact that follow-up durations were limited in many core efficacy studies. Subgroup findings are uncertain for certain types of non-allergic rhinitis, and long-term effects beyond one year of use are not fully established.

Key Studies & References

1. Fluticasone propionate in chronic rhinosinusitis with nasal polyps (CRSwNP): an expert consensus

Common questions about Фликсоназе (FAQ)

---

Q: Can Фликсоназе help with non-allergic nasal congestion?

A: Yes, official regulatory documents state that fluticasone propionate nasal spray is indicated for the treatment of nasal symptoms associated with non-allergic perennial rhinitis (NAPR). Official information indicates the product may be used to help manage year-round nasal symptoms, even when an allergy is not the confirmed cause.

---

Q: Does Фликсоназе treat the symptoms of a common cold?

A: According to the official product information, fluticasone propionate nasal spray is indicated for the temporary relief of symptoms related to hay fever or other upper respiratory allergies. The product is generally not indicated or used for treating the symptoms of a common cold.

---

Q: Can Фликсоназе be used at the same time as an oral antihistamine tablet?

A: Clinical studies reviewed by regulatory authorities indicate that using fluticasone propionate nasal spray in combination with an oral antihistamine tablet was not shown to be more effective than using the nasal spray alone for either nasal or eye allergy symptoms. Consultation with a healthcare provider is appropriate when considering combination therapy.

---

Q: Is Fliksonase available over-the-counter or does it always require a prescription?

A: Fluticasone propionate nasal spray (e.g., 50 mu g/spray) is widely available over-the-counter (OTC) in many regions. Its regulatory status (over-the-counter or prescription) may depend on the product concentration and local regulations.

---

Q: Are there different strengths or formulations of Фликсоназе available?

A: Official drug labeling confirms that the active ingredient fluticasone propionate is available in different dosage forms. This includes the nasal sprays used for rhinitis symptoms, as well as separate metered aerosol inhalers and topical creams or lotions for other, distinct conditions.

---

Q: Is Фликсоназе safe for long-term daily use, for example, throughout an entire allergy season?

A: For adults and adolescents (12 years and older), continuous daily use is generally permitted for up to 6 months; a doctor should be consulted thereafter. For children aged 4 to 11 years, use should not exceed two months per year without professional guidance, due to regulatory advice regarding long-term monitoring of growth rate.

---

Q: Is it true that Фликсоназе can also help with eye-related allergy symptoms, such as itchy eyes?

A: Yes, the product's official indications include the temporary relief of certain eye-related allergy symptoms. This specifically covers itchy and watery eyes, in addition to its effects on nasal symptoms.

---

Q: Does Фликсоназе contain benzalkonium chloride, and is that a concern for long-term use?

A: Official labeling lists benzalkonium chloride as an inactive ingredient in the nasal spray formulation. You should avoid using the product if you have a known hypersensitivity to any of its components.

---

Q: What is the recommended period for a child to use Фликсоназе within a year?

A: Official drug labeling states that children aged 4 to 11 years should check with a healthcare provider if they need to use the product for longer than two months within a year.

---

Q: Can Фликсоназе be used for chronic rhinosinusitis?

A: The fluticasone propionate nasal spray commonly used for allergies is indicated for rhinitis (allergic and non-allergic). However, a different, prescription-only fluticasone propionate product is specifically indicated for the treatment of nasal polyps in adults with or without chronic rhinosinusitis.

---

Q: Are there any dietary restrictions while using Фликсоназе?

A: The only specific food-related restriction mentioned in official labeling is Grapefruit Juice. It is advised against co-consumption because it may interfere with the enzyme that processes the drug, potentially increasing the amount of medicine absorbed systemically. No other general dietary restrictions are listed.

---

Q: Is Фликсоназе known to cause any skin reactions like hives or rash?

A: Official product information notes that in very rare cases, hypersensitivity reactions have been reported after use. These reactions can include skin manifestations such as a rash or hives (urticaria).

---

Q: What are the signs of a severe allergic reaction to Фликсоназе that I should watch for?

A: Official warnings state that signs of a severe allergic reaction (hypersensitivity) may include sudden swelling of the face, tongue, or throat, a rash, trouble breathing, or feeling faint. If any of these signs occur, immediate medical help should be sought.

---

Q: Does Фликсоназе carry the risk of 'rebound congestion' like other nasal sprays?

A: Fluticasone propionate is classified as a corticosteroid, not a nasal decongestant. The official product labeling does not list 'rebound congestion' (rhinitis medicamentosa) as an adverse reaction or risk associated with the recommended use of this spray.

---

Q: Can a person stop using Фликсоназе suddenly without problems?

A: Systemic corticosteroid effects, including adrenal suppression, are possible with prolonged use or use at higher-than-recommended dosages. For continuous long-term use, any decision to stop the medicine should involve consultation with a healthcare professional.

---

Q: Why does Фликсоназе need to be shaken before each use?

A: The product is manufactured as an aqueous suspension, meaning the active drug particles are mixed into a liquid base. Shaking the device gently before each use ensures the drug particles are uniformly dispersed throughout the liquid, which is essential for consistent and correct dosing.

---

Q: Can Фликсоназе cause any oral health issues or white patches in the mouth or nose?

A: Official warnings note that localized infections with the yeast Candida albicans have been observed with use. This type of infection often appears as white patches in the nose or throat. If this occurs, regulatory information advises consulting a healthcare professional as treatment with antifungal therapy may be required.

Official Storage and Disposal Requirements

Flixonase (fluticasone propionate) must be stored according to regulatory labeling to ensure stability and consistent dosing. The medication is required to be stored at controlled room temperature, specifically between 4 C and 30 C. It is mandatory to protect the product from freezing, and it must be kept away from excess heat, moisture, and light. The nasal spray must remain in its original, tightly closed container and always be stored out of the sight and reach of children.

Regarding disposal, regulatory guidance recommends utilizing a drug take-back program. If a take-back option is unavailable, the medicine must be disposed of with household trash by mixing it with an unappealing substance and sealing it in a container. The product must not be flushed down the toilet.